XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.20.1

Collaborative Arrangements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Collaborative Arrangements [Abstract] |
Collaboration Arrangements | Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31,
($ in millions) | 2020 |  | 2019
Alliance revenue | $ | 145 |  |  | $ | 79 |
Cost of sales (1) | 28 |  |  | 19 |
Selling, general and administrative | 33 |  |  | 27 |
Research and development | 36 |  |  | 45 |
($ in millions) | March 31, 2020 |  | December 31, 2019
Receivables from AstraZeneca included in Other current assets | $ | 142 |  |  | $ | 128 |
Payables to AstraZeneca included in Accrued and other current liabilities (2) | 326 |  |  | 577 |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31,
($ in millions) | 2020 |  | 2019
Alliance revenue | $ | 128 |  |  | $ | 74 |
Cost of sales (1) | 35 |  |  | 51 |
Selling, general and administrative | 11 |  |  | 19 |
Research and development | 64 |  |  | 47 |
($ in millions) | March 31, 2020 |  | December 31, 2019
Receivables from Eisai included in Other current assets | $ | 140 |  |  | $ | 150 |
Payables to Eisai included in Accrued and other current liabilities (2) | 425 |  |  | 700 |
Payables to Eisai included in Other Noncurrent Liabilities (3) | 300 |  |  | 525 |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone and future option payments. (3) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31,
($ in millions) | 2020 |  | 2019
Net sales of Adempas recorded by Merck | $ | 56 |  |  | $ | 48 |
Alliance revenue | 53 |  |  | 42 |
Total sales | 109 |  |  | 90 |
Cost of sales (1) | 28 |  |  | 29 |
Selling, general and administrative | 15 |  |  | 8 |
Research and development | 25 |  |  | 30 |
($ in millions) | March 31, 2020 |  | December 31, 2019
Receivables from Bayer included in Other current assets | $ | 50 |  |  | $ | 49 |
Payables to Bayer included in Other Noncurrent Liabilities (2) | 375 |  |  | 375 |
(1) Includes amortization of intangible assets. (2) Represents accrued milestone payment.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration